{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:54Z","timestamp":1792552314182,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bioorg.2025.108242","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T18:57:28Z","timestamp":1738609048000},"page":"108242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Small-molecule BTK inhibitors: From discovery to clinical application"],"prefix":"10.1016","volume":"157","author":[{"given":"Gengren","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baizhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108242_b0005","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108242_b0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1358\/dnp.2008.21.7.1255308","article-title":"Bruton's tyrosine kinase as a drug discovery target","volume":"21","author":"Pan","year":"2008","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.bioorg.2025.108242_b0015","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.108242_b0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clml.2015.11.011","article-title":"Ibrutinib as a Bruton kinase inhibitor in the management of chronic lymphocytic leukemia: a new agent with great promise","volume":"16","author":"Foluso","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bioorg.2025.108242_b0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12032-015-0669-9","article-title":"Ibrutinib: from bench side to clinical implications","volume":"32","author":"Grisafi","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2025.108242_b0030","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjh.16946","article-title":"Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance\/MD Anderson Cancer Center experience","volume":"192","author":"Lewis","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bioorg.2025.108242_b0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hon.2986","article-title":"Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group","volume":"40","author":"Eichenauer","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.108242_b0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of bruton's tyrosine kinase inhibitors to sequester y551 and prevent phosphorylation determines potency for inhibition of fc receptor but not B-cell receptor signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108242_b0045","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2017.03.013","article-title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity","volume":"140","author":"Jennifer","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2025.108242_b0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1078155214561281","article-title":"A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib","volume":"22","author":"Lee","year":"2014","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.bioorg.2025.108242_b0055","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2014-01-453134","article-title":"Src family kinases: at the forefront of platelet activation","volume":"124","author":"Senis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2025.108242_b0060","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/OTT.S249586","article-title":"Ibrutinib in chronic lymphocytic leukemia: clinical applications, drug resistance, and prospects","volume":"13","author":"Zhou","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bioorg.2025.108242_b0065","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s11239-019-01907-9","article-title":"Ibrutinib related bleeding complications in elderly patients with B cell malignancies","volume":"48","author":"Castelli","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.bioorg.2025.108242_b0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cbpa.2015.11.004","article-title":"Covalent targeting of acquired cysteines in cancer","volume":"30","author":"Visscher","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108242_b0075","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.bioorg.2025.108242_b0080","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108242_b0085","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-16-2703","article-title":"B-cell lymphoma patient - derived xenograft models enable drug discovery and are a platform for personalized therapy","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108242_b0090","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/leu.2016.129","article-title":"Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes","volume":"30","author":"Cervantes-Gomez","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.108242_b0095","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1038\/bcj.2017.40","article-title":"Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment","volume":"7","author":"Paulus","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2025.108242_b0100","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.108242_b0105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10456-018-9621-x","article-title":"Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome","volume":"21","author":"Guerra","year":"2018","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bioorg.2025.108242_b0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/1535-7163.MCT-19-0135","article-title":"Ibrutinib potentiates antihepatocarcinogenic efficacy of sorafenib by targeting egfr in tumor cells and btk in immune cells in the stroma","volume":"19","author":"Lin","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108242_b0115","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1080\/10428194.2020.1864352","article-title":"Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia","volume":"62","author":"Ghia","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bioorg.2025.108242_b0120","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0125","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.2147\/OTT.S238832","article-title":"Evaluating the therapeutic potential of zanubrutinib in the treatment of relapsed\/refractory mantle cell lymphoma: evidence to date","volume":"13","author":"Sawalha","year":"2020","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.bioorg.2025.108242_b0130","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2147\/CMAR.S219570","article-title":"Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: a short review on emerging data","volume":"12","author":"Isaac","year":"2020","journal-title":"Cancer Manage. Res."},{"key":"10.1016\/j.bioorg.2025.108242_b0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bioorg.2025.108242_b0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108242_b0145","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.4049\/jimmunol.171.11.5988","article-title":"Function of bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity","volume":"171","author":"Middendorp","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2025.108242_b0150","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/s41467-020-16128-5","article-title":"Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms","volume":"11","author":"Duarte","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108242_b0155","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/pro.575","article-title":"Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures","volume":"20","author":"Kuglstatter","year":"2011","journal-title":"Protein Sci."},{"key":"10.1016\/j.bioorg.2025.108242_b0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/pro.321","article-title":"Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases","volume":"19","author":"Marcotte","year":"2010","journal-title":"Protein Sci."},{"key":"10.1016\/j.bioorg.2025.108242_b0165","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1021\/jm300035p","article-title":"Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies","volume":"55","author":"Lou","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0170","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","article-title":"Targeted covalent drugs of the kinase family","volume":"14","author":"Singh","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108242_b0175","first-page":"675","article-title":"Bruton's TK inhibitors: structural insights and evolution of clinical candidates, Future","volume":"6","author":"Xing","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1747-0285.2010.00993.x","article-title":"Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation","volume":"76","author":"Kutach","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.108242_b0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108242_b0190","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.seminhematol.2024.04.002","article-title":"Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia","volume":"61","author":"Patton","year":"2024","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bioorg.2025.108242_b0195","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2025.108242_b0200","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2025.108242_b0205","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1084\/jem.191.10.1735","article-title":"Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation","volume":"191","author":"Bajpai","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2025.108242_b0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2025.108242_b0215","doi-asserted-by":"crossref","first-page":"35247","DOI":"10.1074\/jbc.M505308200","article-title":"The B cell inhibitory Fc receptor triggers apoptosis by a novel c-Abl family kinase-dependent pathway","volume":"280","author":"Tzeng","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0220","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nrm2803","article-title":"Fine-tuning of GPCR activity by receptor-interacting proteins","volume":"10","author":"Ritter","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.108242_b0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1084\/jem.20020201","article-title":"Chemokine requirements for B cell entry to lymph nodes and Peyer's patches","volume":"196","author":"Okada","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2025.108242_b0230","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1074\/jbc.M110390200","article-title":"G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase","volume":"277","author":"Lowry","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0235","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/38520","article-title":"Direct stimulation of Bruton's tyrosine kinase by G(q)-protein alpha-subunit","volume":"389","author":"Bence","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108242_b0240","doi-asserted-by":"crossref","first-page":"26258","DOI":"10.1074\/jbc.M301484200","article-title":"Bruton's tyrosine kinase is a Toll\/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4","volume":"278","author":"Jefferies","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0245","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ni.2015","article-title":"Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk","volume":"12","author":"Liu","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2025.108242_b0250","doi-asserted-by":"crossref","first-page":"10489","DOI":"10.1074\/jbc.M508892200","article-title":"MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction","volume":"281","author":"Gray","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0255","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.bmcl.2015.01.032","article-title":"Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834","volume":"25","author":"Young","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108242_b0260","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bmcl.2015.11.076","article-title":"Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability","volume":"26","author":"Young","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108242_b0265","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1021\/acsmedchemlett.7b00103","article-title":"Discovery of potent and selective tricyclic inhibitors of Bruton's tyrosine kinase with improved druglike properties","volume":"8","author":"Wang","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108242_b0270","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton's tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0275","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.bmcl.2018.07.008","article-title":"Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit","volume":"28","author":"Qiu","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108242_b0280","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1021\/acs.jmedchem.9b00794","article-title":"Discovery of evobrutinib: an oral, potent, and highly selective, covalent bruton's tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases","volume":"62","author":"Caldwell","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0285","unstructured":"B.L. Hodous, L. Liu-Bujalski, R. Jones, D. Bankston. Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity. 2012, WO 2012170976A2."},{"key":"10.1016\/j.bioorg.2025.108242_b0290","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acs.jmedchem.9b00167","article-title":"Discovery of Branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton's tyrosine kinase (BTK)","volume":"62","author":"Watterson","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0295","doi-asserted-by":"crossref","first-page":"9173","DOI":"10.1021\/acs.jmedchem.6b01088","volume":"59","author":"Watterson","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0300","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1016\/j.bmcl.2015.07.102","article-title":"Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)","volume":"25","author":"Liu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108242_b0305","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1021\/acs.jmedchem.6b00722","volume":"59","author":"De Lucca","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108242_b0310","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.bmcl.2018.07.041","article-title":"Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series","volume":"28","author":"Liu","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108242_b0315","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1021\/cr00039a007","article-title":"Palladium-catalyzed cross-coupling reactions of organoboron compounds","volume":"95","author":"Miyaura","year":"1995","journal-title":"Chem Re"},{"key":"10.1016\/j.bioorg.2025.108242_b0320","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/jpet.111.181545","article-title":"Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic\/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy","volume":"338","author":"Liu","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2025.108242_b0325","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1124\/dmd.111.040840","article-title":"Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor","volume":"39","author":"Liu","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bioorg.2025.108242_b0330","unstructured":"P.A. Blomgren, K.S. Currie, S.H. Lee, S.A. Mitchell, J. Xu, A.C. Schmitt, Z. Zhao, P.E. Zhichkin, D.G. Stafford, J.E. Kroft, Preparation of pyrazinone substituted amides as Btk inhibitors, 2009, WO2009039397."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T21:36:06Z","timestamp":1763847366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825001221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":66,"alternative-id":["S0045206825001221"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108242","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small-molecule BTK inhibitors: From discovery to clinical application","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108242"}}